AstraZeneca and Moderna Therapeutics announce exclusive agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer

AstraZeneca and Moderna Therapeutics announce exclusive agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer

March 21, 2013

 

AstraZeneca today announced an exclusive agreement with Moderna Therapeutics to discover, develop and commercialise pioneering messenger RNA therapeutics™ for the treatment of serious cardiovascular, metabolic and renal diseases as well as cancer. Messenger RNA therapeutics™ are an entirely new treatment approach that enables the body to produce therapeutic protein in vivo, opening up new treatment options for a wide range of diseases that cannot be addressed today using existing technologies.

Flagship Ventures and Merck Research Labs Form Strategic Collaboration to Foster Early-Stage Life Sciences Innovation

Flagship Ventures and Merck Research Labs Form Strategic Collaboration to Foster Early-Stage Life Sciences Innovation

April 10, 2012

Initiative combines Merck’s drug development expertise with Flagship’s experience in building early stage companies

Eleven Biotherapeutics Appoints Wendy L. Dixon, PhD to Board of Directors

Eleven Biotherapeutics Appoints Wendy L. Dixon, PhD to Board of Directors

October 23, 2014

 - Senior Biopharmaceutical Executive with Commercial Leadership Experience from Bristol Myers Squibb and Merck and Co.-

Agios Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of AG-221 in Patients with Advanced Solid Tumors with an IDH2 Mutation

Agios Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of AG-221 in Patients with Advanced Solid Tumors with an IDH2 Mutation

October 21, 2014

AG-221 Now Being Evaluated in Broad Range of Cancers

Moderna to Collaborate with Karolinska Institutet and Karolinska University Hospital on Discovery of New Messenger RNA Therapeutics™

Moderna to Collaborate with Karolinska Institutet and Karolinska University Hospital on Discovery of New Messenger RNA Therapeutics™

October 16, 2014

Strategic research and clinical partnership will advance state-of-the-art discoveries on the use of messenger RNA (mRNA) Therapeutics™ to treat serious diseases
Company to establish Moderna Therapeutics Sweden in Stockholm as first expansion outside the U.S.

Agios Pharmaceuticals Announces Initiation of Four Expansion Cohorts in Phase 1 Study of AG-221

Agios Pharmaceuticals Announces Initiation of Four Expansion Cohorts in Phase 1 Study of AG-221

October 15, 2014

 Once-Daily Oral Dose Selected From Ongoing Phase 1 Study of AG-221 in Hematologic Malignancies

Data From AG-120 to be Presented at EORTC-NCI-AACR 2014; AG-221 and AG-348 Data to be Presented at 2014 American Society of Hematology Annual Meeting

Company to Webcast R&D Day Today

Selecta Announces More than $20 Million in Equity Funding

Selecta Announces More than $20 Million in Equity Funding

October 15, 2014

WATERTOWN, Mass.–(BUSINESS WIRE)–Selecta Biosciences, Inc., a clinical stage biotechnology company developing a novel class of targeted antigen-specific immune therapies, today announced it has secured equity funding of more than $20 million from new and all of Selecta’s existing investors.

Selecta, JDRF and Sanofi Extend Collaboration to Develop a Synthetic Vaccine Particle Immunotherapy for Type 1 Diabetes

Selecta, JDRF and Sanofi Extend Collaboration to Develop a Synthetic Vaccine Particle Immunotherapy for Type 1 Diabetes

October 15, 2014

WATERTOWN, Mass.--(Business Wire)--Selecta Biosciences, Inc., and JDRF,

Acceleron Initiates Phase 1 Clinical Trial with Innovative Muscle Drug ACE-083

Acceleron Initiates Phase 1 Clinical Trial with Innovative Muscle Drug ACE-083

October 14, 2014

-- Locally administered investigational therapeutic designed to increase muscle mass in treated muscles --

-- Fourth internally discovered drug expands Acceleron’s clinical pipeline --

Syros Pharmaceuticals’ Scientific Founders Publish New Research on Gene Control Mechanisms

Syros Pharmaceuticals’ Scientific Founders Publish New Research on Gene Control Mechanisms

October 14, 2014

 Papers in Cell and Molecular Cell expand on importance of super-enhancers in regulating gene expression in normal and inflammatory states

WATERTOWN, MA, October 14, 2014 – Syros Pharmaceuticals, a therapeutics company focused on discovering and developing novel gene control therapies, announced today that recently published research from two of its scientific founders sheds new light on the crucial role of gene control mechanisms in cellular function.